Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR-M (chimeric antigen receptor-modified macrophages) is an adoptive cell therapy engineered to target and suppress tumor growth. These macrophages are modified with a chimeric antigen receptor that directs them to CCR7-positive cells. The cytosolic domain from the Mer receptor tyrosine kinase (MerTK) is incorporated to trigger tumor cell cytotoxicity. This mechanism aims to prevent metastasis and induce systemic anti-tumor immunity by inhibiting the migration of immunosuppressive cells from tumor tissues to distal immune organs. It is currently being investigated for the treatment of malignant tumors, including gliomas and brain metastases originating from breast and lung cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CAR-M.